Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Bonus Content Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorAuthor: Jeffrey Neal Johnson. First Published: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI)-related scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs, roughly $245 per share, creating a divergence that has attracted Wall Street's attention. This rally undercuts the common perception of the healthcare giant as a slow-moving, boring stock. Over the past 30 days, shares have climbed about 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and operational execution. Silver: 20% + 68%
Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now. Click here and start to collect in the next 30 days. For investors watching the ticker today, Feb. 24, 2026, it's worth noting a specific calendar event: today is the ex-dividend date for Johnson & Johnson. That means the stock price will likely drop by the size of the upcoming dividend — $1.30 per share — a mechanical market adjustment rather than a reflection of business performance. For income-focused investors, this technical dip often represents an attractive entry point rather than a sell signal. 64 Years of Unbroken Growth The core argument for holding Johnson & Johnson through turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings — firms that have raised their dividend for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a record that spans multiple recessions, market crashes, and geopolitical shocks. That consistency is rare in a market increasingly focused on speculative growth. Based on an annual payout of $5.20 per share, the stock yields about 2.12%. While higher yields exist in the bond market or in riskier sectors, J&J offers a blend of yield, growth potential, and safety. Management projects free cash flow of roughly $21 billion in 2026, providing a substantial liquidity cushion that helps protect the dividend, fund research, and cover legal expenses without heavy borrowing. For risk-averse investors, one of the most compelling metrics is the stock's beta. Beta measures a stock's historical volatility relative to the overall market (S&P 500). A beta of 1.0 moves in step with the market; Johnson & Johnson's beta is just 0.35. In practice, that means J&J has historically been about 65% less volatile than the broader market — acting as a shock absorber in portfolios overweighted to tech. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about "safe" stocks is that they don't grow. Johnson & Johnson is disproving that with a strategic pivot that appears to be paying off. Management has guided for full-year revenue to top $100 billion for the first time in the company's history, alongside adjusted earnings per share of about $11.53 for 2026. This growth stems from a reinvention of its pharmaceutical division, now branded as Innovative Medicine. Investors had been worried about the patent cliff after Stelara lost exclusivity in 2025. Instead of a revenue collapse, J&J has offset that decline with the rise of new blockbusters. Two key assets are driving that resilience: - Darzalex: An oncology mainstay generating about $14 billion in annual sales, Darzalex has become foundational in treating multiple myeloma.
- Tremfya: Positioned as a successor to Stelara, Tremfya released strong three-year remission data for ulcerative colitis, reinforcing J&J's ability to retain market share in immunology despite older drugs facing generic competition.
The Tech in MedTech: High-Margin Technologies Growth isn't limited to pharmaceuticals. The MedTech division has shifted toward high-growth, high-margin technologies. The acquisition of Shockwave Medical, for example, helped modernize J&J's cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) uses sonic pressure waves to safely break up calcified plaque in arteries — an approach analogous to kidney stone treatment and a material improvement over traditional angioplasty balloons. Owning this technology gives Johnson & Johnson a high-growth asset that complements its heart pump (Abiomed) and surgical businesses. J&J is also pushing into robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete in the expanding soft-tissue robotics market. These high-tech devices carry higher profit margins and foster sticky relationships with hospital systems, creating a long-term earnings tailwind beyond commodity medical supplies. Addition by Subtraction: The Orthopedics Strategy To sustain margin expansion and revenue growth, management is reshaping the company's portfolio. The DePuy Synthes orthopedics business — originally planned as a spin-off — is now reportedly being explored for a possible mega-sale. Divesting a mature, lower-growth orthopedics unit is a classic addition-by-subtraction move. Selling DePuy Synthes would improve J&J's overall growth profile and profit margins and could generate a significant lump-sum payment to fund acquisitions, share buybacks, or other strategic priorities. Legal risks remain a critical part of any analysis. The company is still dealing with talc litigation, including a recent $1.5 billion verdict, and faces a new commercial suit from Bayer over marketing claims for prostate cancer drugs. These headline-grabbing items are still noisy, but they haven't derailed the stock's momentum. The market appears to be looking past those headlines. With more than $20 billion in cash and marketable securities, the potential proceeds from an orthopedics sale, and an expected $21 billion in annual free cash flow, J&J has the financial resources to manage legal settlements without threatening its dividend or core operations. That financial strength turns litigation into a line item on the balance sheet rather than an existential risk. Capital Preservation With Upside Johnson & Johnson has evolved from a sprawling conglomerate into a more focused, high-tech healthcare company. By shedding its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, the company is concentrating on higher-growth opportunities in pharmaceuticals and medical technology. Although the stock is trading near all-time highs and is no longer a deep-value bargain, it offers a compelling mix of capital preservation and upside. A 64-year dividend growth streak, a low volatility profile, and a clear path toward $100 billion in revenue make Johnson & Johnson an attractive option for 2026. For investors tired of tech's unpredictability, J&J shows that, in the current market, boring can be both beautiful and profitable.
| 
